ASX:BNO

Stock Analysis Report

Executive Summary

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the United States.

Rewards

Revenue is forecast to grow 14.32% per year

Risk Analysis

Earnings are forecast to decline by an average of -5.8% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Has less than 1 year of cash runway

Highly volatile share price over past 3 months

+ 2 more risks


Snowflake Analysis

Imperfect balance sheet and overvalued.

Share Price & News

How has Bionomics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BNO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.1%

BNO

-0.06%

AU Biotechs

-0.07%

AU Market


1 Year Return

-25.6%

BNO

55.8%

AU Biotechs

19.1%

AU Market

Return vs Industry: BNO underperformed the Australian Biotechs industry which returned 55.8% over the past year.

Return vs Market: BNO underperformed the Australian Market which returned 19.1% over the past year.


Shareholder returns

BNOIndustryMarket
7 Day-2.1%-0.06%-0.07%
30 Day-17.3%5.7%-0.6%
90 Day151.4%19.5%0.4%
1 Year-25.6%-25.6%57.7%55.8%25.0%19.1%
3 Year-73.0%-73.0%195.7%185.1%36.0%17.4%
5 Year-78.6%-78.6%227.2%205.9%63.2%26.5%

Price Volatility Vs. Market

How volatile is Bionomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bionomics undervalued compared to its fair value and its price relative to the market?

2.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BNO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BNO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BNO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BNO is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BNO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BNO is good value based on its PB Ratio (2.9x) compared to the AU Biotechs industry average (3x).


Next Steps

Future Growth

How is Bionomics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-5.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BNO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BNO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BNO's revenue (14.3% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: BNO's revenue (14.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BNO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Bionomics performed over the past 5 years?

-23.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BNO is currently unprofitable.

Growing Profit Margin: BNO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNO is unprofitable, and losses have increased over the past 5 years at a rate of -23.3% per year.

Accelerating Growth: Unable to compare BNO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (10.4%).


Return on Equity

High ROE: BNO has a negative Return on Equity (-54.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Bionomics's financial position?


Financial Position Analysis

Short Term Liabilities: BNO's short term assets (A$25.1M) exceed its short term liabilities (A$13.8M).

Long Term Liabilities: BNO's short term assets (A$25.1M) exceed its long term liabilities (A$22.2M).


Debt to Equity History and Analysis

Debt Level: BNO's debt to equity ratio (96.6%) is considered high.

Reducing Debt: BNO's debt to equity ratio has increased from 1.5% to 96.6% over the past 5 years.


Balance Sheet

Inventory Level: BNO has a low level of unsold assets or inventory.

Debt Coverage by Assets: BNO's debt is covered by short term assets (assets are 1.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BNO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Bionomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.5%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BNO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BNO's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Bionomics's salary, the management and board of directors tenure and is there insider trading?

1.1yrs

Average management tenure


CEO

Bionomics has no CEO, or we have no data on them.


Management Age and Tenure

1.1yrs

Average Tenure

Experienced Management: BNO's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

65.5yo

Average Age

Experienced Board: BNO's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellAU$470,14113 Jun 19
New York Life Investment Management LLC
EntityCompany
Shares6,469,148
Max PriceAU$0.086

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.1%.


Management Team

  • Errol B. De Souza (66yo)

    Executive Chairman

    • Tenure: 3.3yrs
    • Compensation: AU$318.96k
  • Paul Rolan

    Consultant Chief Medical Officer of Clinical Neuroscience

    • Tenure: 0yrs
    • Compensation: AU$102.00k
  • Jack Moschakis

    Legal Counsel & Company Secretary

    • Tenure: 4.6yrs
    • Compensation: AU$448.05k
  • Adrian Hinton

    Acting Chief Financial Officer

    • Tenure: 0.6yrs
    • Compensation: AU$204.60k

Board Members

  • Tim Harris (68yo)

    Scientific Advisor

    • Tenure: 3.3yrs
  • Ann Hayes

    Scientific Advisor

    • Tenure: 0yrs
  • Errol B. De Souza (66yo)

    Executive Chairman

    • Tenure: 3.3yrs
    • Compensation: AU$318.96k
  • Peter Turner (70yo)

    Non-Executive Director

    • Tenure: 3.5yrs
    • Compensation: AU$113.29k
  • David Wilson (55yo)

    Non-Executive Director

    • Tenure: 3.5yrs
    • Compensation: AU$103.29k
  • Alan Fisher (65yo)

    Non-Executive Director

    • Tenure: 3.3yrs
    • Compensation: AU$114.29k
  • Fiona McLaughlin (49yo)

    Scientific Advisor

    • Tenure: 0yrs
  • Paul Fitzgerald

    Scientific Advisor

    • Tenure: 0yrs
  • Philippe Danjou

    Scientific Advisor

    • Tenure: 0yrs
  • Fiona Thomson

    Scientific Advisor

    • Tenure: 0yrs

Company Information

Bionomics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bionomics Limited
  • Ticker: BNO
  • Exchange: ASX
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$49.022m
  • Shares outstanding: 544.69m
  • Website: https://www.bionomics.com.au

Location

  • Bionomics Limited
  • 31 Dalgleish Street
  • Thebarton
  • South Australia
  • 5031
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BNOASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 1999
B1NDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 1999
BNOE.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 1999
BNOCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 1999

Biography

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia, France, and the U ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/10 10:31
End of Day Share Price2019/12/09 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.